An Act relative to newborn screenings for congenital cytomegalovirus
Massachusetts would require newborn screening for congenital cytomegalovirus to enable early detection and antiviral treatment preventing hearing loss and developmental damage.
Massachusetts would require newborn screening for congenital cytomegalovirus to enable early detection and antiviral treatment preventing hearing loss and developmental damage.
SD 1421 would require Massachusetts to add congenital cytomegalovirus (CMV) to the state's newborn screening program. The bill mandates testing all newborns for this viral infection, which can cause hearing loss, vision problems, developmental delays, and other serious complications if left undetected and untreated.
Early detection of congenital CMV allows for antiviral treatment that can prevent or reduce severity of hearing loss and neurological damage in affected infants. Currently, Massachusetts does not screen for CMV despite it being one of the most common congenital infections in the U.S., affecting approximately 1 in 200 newborns. This gap means affected infants may not receive timely intervention, potentially resulting in permanent disabilities that could have been mitigated.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.